Concept Medical unveils promising 3-year data for sirolimus balloon therapy

The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease

KIMS Hospitals Thane treats 88-Year-old PAD patient using advanced excimer laser atherectomy

Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility

Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment

The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals

Cardiological Society of India releases first Indian guidelines for dyslipidemia management

Dyslipidemia is a critical risk factor for cardiovascular diseases

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition

World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China

Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.